Accès gratuit
Med Sci (Paris)
Volume 32, Numéro 8-9, Août–Septembre 2016
Page(s) 739 - 745
Section M/S Revues
Publié en ligne 12 septembre 2016
  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012 ; 30 : 2212–2219. [CrossRef] [PubMed]
  2. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004 ; 350 : 1118–1129. [CrossRef] [PubMed]
  3. Shimakawa Y, Lemoine M, Njai HF, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. Gut 2015 ; pii: gutjnl-2015-309892. doi : 10.1136/gutjnl-2015-309892.
  4. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975 ; 292 : 771–774. [CrossRef] [PubMed]
  5. Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982 ; 146 : 198–204. [CrossRef] [PubMed]
  6. Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: the third trimester intervention. Hepatology 2014 ; 60 : 448–451. [CrossRef] [PubMed]
  7. Maupas P, Goudeau A, Coursaget P, et al. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study. Intervirology 1978 ; 10 : 196–208. [CrossRef] [PubMed]
  8. Galibert F, Mandart E, Fitoussi F, et al. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979 ; 281 : 646–650. [CrossRef] [PubMed]
  9. Pasek M, Goto T, Gilbert W, et al. Hepatitis B virus genes and their expression in E. coli. Nature 1979 ; 282 : 575–579. [CrossRef] [PubMed]
  10. Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982 ; 298 : 347–350. [CrossRef] [PubMed]
  11. Michel ML, Pontisso P, Sobczak E, et al. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proc Natl Acad Sci USA 1984 ; 81 : 7708–7712. [CrossRef]
  12. Chiang CJ, Yang YW, You SL, et al. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013 ; 310 : 974–976. [CrossRef] [PubMed]
  13. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009 ; 101 : 1348–1355. [CrossRef] [PubMed]
  14. Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 2011 ; 22 : 523–527. [CrossRef] [PubMed]
  15. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011 ; 54 : 801–807. [CrossRef] [PubMed]
  16. Qu C, Chen T, Fan C, et al. Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. PLoS Med 2014 ; 11 : e1001774. [CrossRef]
  17. Werner JM, Abdalla A, Gara N, et al. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013 ; 145 : 1026–1034. [CrossRef] [PubMed]
  18. Li ZK, Nie JJ, Li J, Zhuang H. The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 2013 ; 31 : 4355–4361. [CrossRef] [PubMed]
  19. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011 ; 305 : 1432–1440. [CrossRef] [PubMed]
  20. Rey D, Piroth L, Wendling MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis 2015 ; 15 : 1283–1291. [CrossRef] [PubMed]
  21. Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008 ; 73 : 856–862. [CrossRef] [PubMed]
  22. Filippelli M, Lionetti E, Gennaro A, et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 2014 ; 20 : 10383–10394. [CrossRef] [PubMed]
  23. Krawczyk A, Ludwig C, Jochum C, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine 2014 ; 32 : 5077–5082. [CrossRef] [PubMed]
  24. Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005 ; 366 : 1379–1384. [CrossRef] [PubMed]
  25. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J Infect Dis 2008 ; 197 : 1419–1426. [CrossRef] [PubMed]
  26. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000 ; 355 : 561–565. [CrossRef] [PubMed]
  27. Romano L, Paladini S, Galli C, et al. Hepatitis B vaccination. Hum Vaccin Immunother 2015 ; 11 : 53–57. [CrossRef]
  28. Hsu HY, Chang MH, Ni YH, et al. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010 ; 201 : 1192–1200. [CrossRef] [PubMed]
  29. Locarnini S, Shouval D. Commonly found variations/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance. J Virol 2014 ; 88 : 6532. [CrossRef] [PubMed]
  30. Launay O, Floret D. Vaccination contre l’hépatite B. Med Sci (Paris) 2015 ; 31 : 551–558. [CrossRef] [EDP Sciences]
  31. Denis F, Cohen R, Martinot A, et al. Evolution of hepatitis B vaccine coverage rates in France between 2008 and 2011. Med Mal Infect 2013 ; 43 : 272–278. [CrossRef] [PubMed]
  32. Antona D, Lefort MJ, Larsen C, Levy-Bruhl D. L’infection par le virus de l’hépatite B : une maladie sexuellement transmissible. Bull Epidemiol Hebd 2011 ; 26–27-28 : 307–310.
  33. Stahl JP, Denis F, Gaudelus J, et al. Hepatitis B vaccination and adolescents: a lost generation. Med Mal Infect 2016 ; 46 : 1–3. [CrossRef]
  34. Liang TJ, Block TM, McMahon BJ, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015 ; 62 : 1893–1908. [CrossRef] [PubMed]
  35. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 ; 5 : 215–229. [CrossRef] [PubMed]
  36. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999 ; 180 : 15–26. [CrossRef] [PubMed]
  37. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011 ; 54 : 1286–1296. [CrossRef] [PubMed]
  38. Mancini-Bourgine M, Fontaine H, Scott-Algara D, et al. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004 ; 40 : 874–882. [CrossRef] [PubMed]
  39. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012 ; 12 : 201–213. [CrossRef] [PubMed]
  40. Martin P, Dubois C, Jacquier E, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015 ; 64 : 1961–1971. [CrossRef] [PubMed]
  41. Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014 ; 10 : e1003856. [CrossRef] [PubMed]
  42. Testoni B, Zoulim F. Liver capsule: validated and potential novel targets to treat hepatitis B virus. Hepatology 2015 ; 62 : 1619. [CrossRef] [PubMed]
  43. Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: state-of-the-art and unresolved questions. Report of the ANRS workshop on HBV cure. Gut 2015 ; 64 : 1314–1326. [CrossRef] [PubMed]
  44. Launay O, Floret D. Vaccination contre l’hépatite B. Med Sci (Paris) 2015 ; 31 : 551–558. [CrossRef] [EDP Sciences]
  45. Floret D. Les résistances à la vaccination. Med Sci (Paris) 2010 ; 26 : 1087–1093. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.